BofA lowered the firm’s price target on Sarepta to $164 from $169 and keeps a Buy rating on the shares after the company announced that the FDA has changed its prior stance and now intends to hold an advisory committee meeting, or ad com, for SRP-9001. This "quick pivot gives us a bit of whiplash," but the firm had always assumed an ad com was likely and thinks Sarepta is "well-prepared," the analyst tells investors. The logistics of scheduling an ad com increases the burden on the agency for what is already a short review timeline, so the firm thinks the likelihood of a three month PDUFA extension is higher post the ad com for logistical reasons, though this does not change BofA’s view on the approvability of ‘9001.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta Plunges after Regulatory Update
- Sarepta says advisory committee meeting to be held for SRP-9001
- Sarepta Therapeutics Skyrockets after String of Good News
- Sarepta price target raised to $226 from $195 at RBC Capital
- 3 Stocks to Buy Today, 3/1/2023, According to Top Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue